8 completed, 2 unknown, 1 enrolling by invitation, 1 recruiting. 13 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Unknown 2, Enrolling by invitation 1, Recruiting 1, Terminated 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Functional Dyspepsia: new trials by email Literature Review of Functional Dyspepsia trials Research Report on Functional Dyspepsia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy - Functional Dyspepsia | Phase 2 / Phase 3 | Recruiting | Md. Moktadirul Hoque Shuvo | 120 | 2025-07-01 | 2026-05-07 |
| A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia Glutamine, Placebo - Functional Dyspepsia | Phase 1 / Phase 2 | Completed | David J. Cangemi | 12 | 2023-02-16 | 2026-02-03 |
| Tradipitant for Functional Dyspepsia Tradipitant, Placebo - Functional Dyspepsia | Phase 2 | Enrolling by invitation | Xiao Jing (Iris) Wang | 60 | 2023-02-09 | 2026-07-16 |
| Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients Aolanti Weipang Tablets, Placebo - Functional Dyspepsia | Phase 2 | Unknown | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 236 | 2019-06-10 | 2019-06-03 |
| Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules Qizhi Weitong Granules, Mosapride Citrate Tablets - Functional Dyspepsia, Traditional Chinese Medicine | Phase 1 / Phase 2 | Unknown | Xiyuan Hospital of China Academy of Chinese Medical Sciences | 384 | 2017-02-01 | 2020-02-28 |
| A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia YH12852 0.1 mg, YH12852 0.25 mg, YH12852 0.5 mg - Functional Dyspepsia | Phase 2 | Terminated | Yuhan Corporation | 12 | 2015-10-01 | 2022-01-13 |
| Rifaximin for Functional Dyspepsia Rifaximin, Placebo - Functional Dyspepsia | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 95 | 2013-01-01 | 2015-12-02 |
| Acupuncture for Patients With Function Dyspepsia acupuncture, sham acupuncture - Functional Dyspepsia, Postprandial Distress Syndrome | Phase 2 / Phase 3 | Completed | Chengdu University of Traditional Chinese Medicine | 200 | 2012-09-01 | 2014-12-02 |
| New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study Rabeprazole and Amoxicillin, Amoxicillin and Rabeprazole - Functional Dyspepsia | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 40 | 2011-04-01 | 2012-01-20 |
| A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204) Rabeprazole, Placebo - Functional Dyspepsia | Phase 2 | Completed | Eisai Co., Ltd. | 338 | 2010-04-01 | 2013-12-24 |
| To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia Z-338 - Functional Dyspepsia | Phase 2 | Completed | Zeria Pharmaceutical | 282 | 2006-04-01 | 2015-05-28 |
| To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia Z-338 - Functional Dyspepsia | Phase 2 | Completed | Zeria Pharmaceutical | 440 | 2006-04-01 | 2009-01-14 |
| Itopride in Functional Dyspepsia:a Dose Finding Study Itopride (drug) - Functional Dyspepsia | Phase 2 / Phase 3 | Completed | Royal Adelaide Hospital | 500 | 2000-12-01 | 2006-05-04 |
Dyspepsia (2)
Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2)
Rabeprazole (2) · Z 338 (2) · Acupuncture Therapy (1) · Amoxicillin (1) · Glutamine (1) · Pharmaceutical Preparations (1) · Rifaximin (1) · YH12852 (1) · itopride (1) · mosapride (1)
Zeria Pharmaceutical (2) · Chengdu University of Traditional Chinese Medicine (1) · David J. Cangemi (1) · Eisai Co., Ltd. (1) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1) · Md. Moktadirul Hoque Shuvo (1) · Royal Adelaide Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · The University of Hong Kong (1) · Xiao Jing (Iris) Wang (1) · Xiyuan Hospital of China Academy of Chinese Medical Sciences (1) · Yuhan Corporation (1)
China (5) · Japan (2) · United States (2) · Bangladesh (1) · Belgium (1) · Germany (1) · South Korea (1)
David Cangemi, MD (1) · Fan-rong Liang, MD (1) · Gerald J Holtmann, MD (1) · Jan Tack, PhD, MD (1) · Li X B, M.D., Ph.D. (1) · Michio Hongo, Professor (1) · Poong Lyul Lee, MD, Ph.D (1) · Wai Keung Leung, MD (1) · Xiao Ke (1) · Yoshiumi Okubo (1)